Joji Mori - Concepedia

Author

Joji Mori

Also Known As

J. Mori, Joji Mori

Publications

216

Citations

H-Index

Concepts

All Affiliations

Joji Mori is an author at Eli Lilly (Japan) specializing in radiation oncology, cancer therapeutics, and cancer research.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	61
2	Pharmacology	1	1	61
3	Cancer Therapeutics	1	1	61
4	Cancer Research	1	1	61
5	Oncology	1	1	61

Joji Mori

Publications

195

Citations

H-Index

Page 1

	Year	Citations
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Cancer Chemotherapy and Pharmacology OncologySingle AgentMedicineImmune Checkpoint InhibitorAnti-cancer Agent	2016	61
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Dementia and Geriatric Cognitive Disorders Extra	2011	50
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors Toshihiko Doi, Masaomi Tajimi, Joji Mori, Investigational New Drugs	2020	30
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Masato Takahashi, Eriko Tokunaga, Joji Mori, Breast Cancer	2021	30
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Breast Cancer	2021	24

Page 1